Clinical Trial

Use of the Methoxyflurane as Pain-killer in the Prehospital Management of Acute Myocardial Infarction

Study acronym: MAMI
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
* Chest pain is the main symptom of acute myocardial infarction. A precocious analgesic treatment is justified by patient's comfort and unfavorable hemodynamic consequences of persistent pain. Morphine is the painkiller historically prescribed in this situation. Morphine has never been evaluated vs placebo and is strongly suspected to decrease oral anti-platelet efficacy. Then, morphine has been downgraded, in the 2017 European guidelines (European Society of Cardiology - ESC) from I to IIa. To find alternative treatment is required. * The methoxyflurane is an anesthetic gas used in emergency setting for about twenty years. It is now commonly used in France. Its analgesic properties have been demonstrated. Its main advantages are its maneuverability as it is delivered by inhalation, i.e. without (before) any venous access and self-administered by the patient. Tolerability is good. It could be an excellent alternative to morphine.
Trial Details
NCT Number NCT07445737
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Collaborators: Medical Developments International Limited
Conditions STEMI - ST Elevation Myocardial Infarction
Enrollment 700 participants
Start Date 2026-06
Primary Completion 2029-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-03